NOZINAN

This brand name is authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Malta, Netherlands, New Zealand, Tunisia, UK.

Active ingredients

The drug NOZINAN contains one active pharmaceutical ingredient (API):

1	Levomepromazine UNII 5KN5Y9V01K - LEVOMEPROMAZINE MALEATE
	Levomepromazine resembles chlorpromazine and promethazine in the pattern of its pharmacology. It possesses anti-emetic, antihistamine and anti-adrenaline activity and exhibits a strong sedative effect.
	Read more about Levomepromazine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NOZINAN Tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
NOZINAN Solution for injection / infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AA02	Levomepromazine	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AA Phenothiazines with aliphatic side-chain
Discover more medicines within N05AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	01927698
EE	Ravimiamet	1882122
FR	Base de données publique des médicaments	60548802, 60669978, 63148279, 64026417, 67348996, 67477165, 68270422, 69074348, 69192161
GB	Medicines & Healthcare Products Regulatory Agency	162146, 25940, 373997, 376962, 381567, 41831
HR	Agencija za lijekove i medicinske proizvode	HR-H-260996650, HR-H-983495354
IE	Health Products Regulatory Authority	36501
MT	Medicines Authority	AA565/22303
NL	Z-Index G-Standaard	12824119
NL	Z-Index G-Standaard, PRK	2097, 6580
NZ	Medicines and Medical Devices Safety Authority	21069, 21070, 713, 714, 715
TN	Direction de la Pharmacie et du Médicament	6390091, 6390092